Christopher J Longo1, Margaret I Fitch2, Laura Banfield3, Paul Hanly4, K Robin Yabroff5, Linda Sharp6. 1. Health Policy and Management, DeGroote School of Business, McMaster University, Hamilton, Ontario, Canada. cjlongo@mcmaster.ca. 2. Bloomberg Faculty of Nursing, University of Toronto, Toronto, Ontario, Canada. 3. Health Sciences Library, McMaster University, Hamilton, Ontario, Canada. 4. National College of Ireland, Dublin, Ireland. 5. Health Services Research, American Cancer Society, Atlanta, GA, USA. 6. Population Health Sciences Institute, Newcastle University Centre for Cancer, Newcastle University, Newcastle upon Tyne, UK.
Abstract
PURPOSE: Financial toxicity related to cancer diagnosis and treatment is a common issue in developed countries. We seek to systematically summarize the extent of the issue in very high development index countries with publicly funded healthcare. METHODS: We identified articles published Jan 1, 2005, to March 7, 2019, describing financial burden/toxicity experienced by cancer patients and/or informal caregivers using OVID Medline Embase and PsychInfo, CINAHL, Business Source Complete, and EconLit databases. Only English language peer-reviewed full papers describing studies conducted in very high development index countries with predominantly publicly funded healthcare were eligible (excluded the USA). All stages of the review were evaluated in teams of two researchers excepting the final data extraction (CJL only). RESULTS: The searches identified 7117 unique articles, 32 of which were eligible. Studies were undertaken in Canada, Australia, Ireland, UK, Germany, Denmark, Malaysia, Finland, France, South Korea, and the Netherlands. Eighteen studies reported patient/caregiver out-of-pocket costs (range US$17-US$506/month), 18 studies reported patient/caregiver lost income (range 17.6-67.3%), 14 studies reported patient/caregiver travel and accommodation costs (range US$8-US$393/month), and 6 studies reported financial stress (range 41-48%), strain (range 7-39%), or financial burden/distress/toxicity among patients/caregivers (range 22-27%). The majority of studies focused on patients, with some including caregivers. Financial toxicity was greater in those with early disease and/or more severe cancers. CONCLUSIONS: Despite government-funded universal public healthcare, financial toxicity is an issue for cancer patients and their families. Although levels of toxicity vary between countries, the findings suggest financial protection appears to be inadequate in many countries.
PURPOSE:Financial toxicity related to cancer diagnosis and treatment is a common issue in developed countries. We seek to systematically summarize the extent of the issue in very high development index countries with publicly funded healthcare. METHODS: We identified articles published Jan 1, 2005, to March 7, 2019, describing financial burden/toxicity experienced by cancerpatients and/or informal caregivers using OVID Medline Embase and PsychInfo, CINAHL, Business Source Complete, and EconLit databases. Only English language peer-reviewed full papers describing studies conducted in very high development index countries with predominantly publicly funded healthcare were eligible (excluded the USA). All stages of the review were evaluated in teams of two researchers excepting the final data extraction (CJL only). RESULTS: The searches identified 7117 unique articles, 32 of which were eligible. Studies were undertaken in Canada, Australia, Ireland, UK, Germany, Denmark, Malaysia, Finland, France, South Korea, and the Netherlands. Eighteen studies reported patient/caregiver out-of-pocket costs (range US$17-US$506/month), 18 studies reported patient/caregiver lost income (range 17.6-67.3%), 14 studies reported patient/caregiver travel and accommodation costs (range US$8-US$393/month), and 6 studies reported financial stress (range 41-48%), strain (range 7-39%), or financial burden/distress/toxicity among patients/caregivers (range 22-27%). The majority of studies focused on patients, with some including caregivers. Financial toxicity was greater in those with early disease and/or more severe cancers. CONCLUSIONS: Despite government-funded universal public healthcare, financial toxicity is an issue for cancerpatients and their families. Although levels of toxicity vary between countries, the findings suggest financial protection appears to be inadequate in many countries.
Authors: Alessandro Liberati; Douglas G Altman; Jennifer Tetzlaff; Cynthia Mulrow; Peter C Gøtzsche; John P A Ioannidis; Mike Clarke; P J Devereaux; Jos Kleijnen; David Moher Journal: BMJ Date: 2009-07-21
Authors: Cheryl K Altice; Matthew P Banegas; Reginald D Tucker-Seeley; K Robin Yabroff Journal: J Natl Cancer Inst Date: 2016-10-20 Impact factor: 13.506
Authors: Alexander Fabian; Justus Domschikowski; Wolfgang Greiner; Gunnar Bockelmann; Elias Karsten; Alexander Rühle; Nils H Nicolay; Anca L Grosu; Jürgen Dunst; David Krug Journal: Strahlenther Onkol Date: 2022-04-25 Impact factor: 3.621
Authors: Fiona Crawford-Williams; Bogda Koczwara; Raymond J Chan; Janette Vardy; Karolina Lisy; Julia Morris; Mahesh Iddawela; Gillian Mackay; Michael Jefford Journal: Support Care Cancer Date: 2022-01-15 Impact factor: 3.603
Authors: Christopher J Longo; Margaret I Fitch; Jonathan M Loree; Linda E Carlson; Donna Turner; Winson Y Cheung; Darin Gopaul; Janet Ellis; Jolie Ringash; Maria Mathews; Jim Wright; Christiaan Stevens; David D'Souza; Robin Urquhart; Tuhin Maity; Fanor Balderrama; Evette Haddad Journal: Support Care Cancer Date: 2021-01-05 Impact factor: 3.603
Authors: Melissa S Y Thong; Daniela Doege; Linda Weißer; Lena Koch-Gallenkamp; Heike Bertram; Andrea Eberle; Bernd Holleczek; Alice Nennecke; Annika Waldmann; Sylke Ruth Zeissig; Ron Pritzkuleit; Michael Schlander; Hermann Brenner; Volker Arndt Journal: J Cancer Res Clin Oncol Date: 2021-10-13 Impact factor: 4.553
Authors: Carla Thamm; Jennifer Fox; Nicolas H Hart; Joel Rhee; Bogda Koczwara; Jon Emery; Kristi Milley; Rebecca L Nund; Raymond J Chan Journal: Support Care Cancer Date: 2021-07-26 Impact factor: 3.603